ASARINA PHARMA AB (publ) ANNUAL REPORT 2021 RELEASED

Peter Nordkild, CEO: “Despite the challenges of the last year we remain committed to our goal of providing new effective therapy to patients with various neurological disorders. Topline data for our phase IIa study in Tourette are still expected in Q1 of 2023 and the study remains fully funded. We maintain our full focus on Sepranolone’s potential and move forward with focus and optimism.”

FINANCIAL HIGHLIGHTS

• Total operating costs were reduced by more than 50% to SEK 38.3 million.
• R&D costs dropped to SEK 29.9 millionfrom SEK 63.7 million in 2020.The Company received a convertible loan of SEK 5.3 million from Östersjöstiftelsen. We expect the cash position of SEK 21.7 million at year-end to be sufficient to finance the phase IIa Tourette study.

R&D HIGHLIGHTS

FEBRUARY 11: Prof. Marco Bortolato (Univ. of Utah, USA) presents two sets of new preclinical data confirming that Sepranolone suppresses tics in Tourette Syndrome with no observable side-effects.

JUNE 8: The US Patent and Trademark Office grants a patent for Sepranolone for the treatment of Tourette, Obsessive-Compulsive Disorder (OCD) and pathological gambling.

JUNE 23: Topline results from Asarina’s phase IIa study of Sepranolone for menstrual migraine find that a statistically significant difference compared to placebo was not obtained in the study’s primary and secondary endpoints.

SEPTEMBER 28: A post hoc analysis of Sepranolone for PMDD (Premenstrual Dysphoric Disorder) finds that Sepranolone in a 10 mg dose demonstrated a significant treatment effect compared to placebo, when examined in an extended 9-day analysis of symptom reduction. (The original study targeted a 5-day treatment period).

DECEMBER 22: Administrative approval of the two study sites for our phase IIa clinical study in Tourette syndrome was obtained following a five-month delay due to an administrative backlog in Copenhagen’s Region Hovedstaden city government.

To read the Report in full please visit: https://asarinapharma.com/investors/financial-reports/

For further information, please contact:

Peter Nordkild, CEO

Phone: +45 25 47 16 46

E-mail: peter.nordkild@asarinapharma.com

Jakob Dynnes Hansen, CFO

Phone: +45 5132 3698

E-mail: jakob.dynnes@asarinapharma.com

Certified Adviser

Erik Penser Bank AB

Phone: +46 8-463 83 00

Mail: certifiedadviser@penser.se

ABOUT ASARINA PHARMA

We are a Swedish biotech company developing Sepranolone for allopregnanolone-induced stress- and compulsivity-driven disorders. Our product pipeline is built on over 40 years of research into allopregnanolone-related neurological disorders. With our new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) we aim to deliver a new generation of safe, efficacious drugs for neurological conditions from Tourette syndrome to Obsessive compulsive disorder that still lack safe, efficacious pharmaceutical treatments.

The information above was provided by the CEO of Asarina Pharma AB (publ), for publication on April 6, 2022.